Medytox, a young global biopharmaceutical company, is recognized all around the world beyond domestic boundaries.

History

Beginning
Growth
Take-off

2006
Selected as "World-class Product" for Meditoxin® (Ministry of Commerce Industry and Energy)
Obtained approval from KFDA for Korea’s first, world’s fourth botulinum toxin type A, Meditoxin® 100U
2004
Obtained KGMP approval for Medytox Plant I (Ochang)
2002
Completed Medytox Plant I (Ochang) construction
2001
Established "Microbial Toxin R&D Center" at Medytox
2000
Established Medytox Inc. (May 2nd)

2013
Selected as Forbes "2013 Asia's 200 Best Under a Billion List"
Selected as 2013 Innovative Pharmaceutical Company accreditation (Ministry of Health & Welfare)
Selected as 2013 KOSDAQ Hidden Champion (Korea Stock Exchange)
Obtained approval from MFDS for Neuramis Deep®
Obtained approval from MFDS for Meditoxin® 150U
Obtained approval from MFDS for worlds’ first, non-animal-derived liquid formulation botulinum toxin type A Innotox® 25U
Established Medytox Korea (domestic sales corporation)
Signed a License Agreement with Allergan Inc. (US) for new formulation of new botulinum toxin type A
2012
Completed global phase II clinical study for new formulation of botulinum toxin product (Australian Therapeutic Goods Administration (TGA))
Gained indication for the treatment of post stroke upper limb local muscle spasticity for Meditoxin®
Selected as 2012 Innovative Pharmaceutical Company (Ministry of Health & Welfare)
Groundbreaking of cGMP compliant Medytox Plant II (Osong)
Selected as 2012 KOSDAQ Hidden Champion (Korea Stock Exchange)
Selected as an exemplary taxpayer and received National Tax Services Commissioner’s Commendation
Reached 1M vial Meditoxin® release mark
2011
Received $10M Export Tower Award
Received CE marking for hyaluronic acid filler Neuramis® Deep
Approved for global phase II clinical study for a new botulinum toxin product (Australian Therapeutic Goods Administration (TGA))
Gained indication for glabellar wrinkles improvement for Meditoxin®
Obtained KGMP approval for Filler Department of Medytox Plant I (Ochang)
Selected as a World Advanced Technology Center (WATC) (Ministry of Knowledge Economy)
2010
Approved for global phase I clinical study for a new formulation of botulinum toxin product (Australian Therapeutic Goods Administration (TGA))
Announced new CI (Company Identity) for Medytox Inc.
Gained insurance coverage of indications for foot deformities due to spasticity in pediatric cerebral palsy patients with Meditoxin®
Selected as INNO-BIZ (Innovation Business)
Gained indication of treatment for foot deformity due to spasticity in pediatric cerebral palsy patients with Meditoxin®
Obtained approval from KFDA for Meditoxin® 50U
2009
Achieved No.1 market share in the botulinum toxin market in Korea,
Received a $5M Export Tower Award
Obtained approval from KFDA for Meditoxin® 200U
Listed on KOSDAQ
2008
Selected as "Bio Star Enterprise" (Ministry of Knowledge Economy)
Selected as a Promising Export Firm
2007
Received 2007 Prime Minister Commendation by Venture Korea
First registered Meditoxin® in overseas market (Bolivia) (product name: Neuronox®)
Opened Medytox Korea Seoul office

2017
Began first open recruitment
Completed Medytox Gwanggyo R&D Center construction
Established a Thailand joint venture "MedyCeles"
Relocated to Medytox Building (Daechi-dong, Gangnam-gu, Seoul)
2016
Received $30M Export Tower Award
Exceeded 100 billion KRW mark in total annual sales
Completed Medytox Plant III (Osong) construction, the biggest scale in Korea
Obtained drug approval for non-animal-derived botulinum toxin type A which refined only main active ingredients, Coretox® 100U
Started a scholarship program to support talents for the fields of life science in Korea
2015
Selected as Forbes "Asia’s 200 Best Under a Billion List 2015"
Received $20M Export Tower Award
Received "Minister of Industry Commendation" on 5th Industrial Technology Protection Day
Received the "Presidential Commendation of Technology Development Division with Special Merit" (Ministry of Trade, Industry, and Energy)
Received the "Best Trader of the 2015 Award" (Ministry of Trade, Industry, and Energy, Korea International Trade Association)
Obtained approval from MFDS for Neuramis® Lidocaine Series
Obtained approval from MFDS for Innotox® 50U
Established a Japan local subsidiary "MDT International Inc."
Established a Hong Kong joint venture "Medytox Hong Kong"
Established a China joint venture "Medybloom China"
Established a Taiwan joint venture "Medytox Taiwan"
2014
Obtained approval from MFDS for Neuramis® Deep Lidocaine
Selected as "K-Brain Power" (Ministry of Trade, Industry, and Energy)
Received the Grand Prize at the "6th Korea Technology Award" (Ministry of Trade, Industry, and Energy)
cGMP / EU GMP compliant Medytox Plant II (Osong) construction